跳到正文
原文
Medical Xpress·· 3 小时前精选AI 评分76

研究显示改进型血液检测准确性与脑脊液检测相当,有望为阿尔茨海默病诊断提供更低创选择

Improved blood test offers less invasive way to detect Alzheimer's disease

AI 导读

瑞典隆德大学发表在《Nature Aging》的研究显示,用于检测阿尔茨海默病的改进型血液检测(测量p-tau217蛋白)在识别疾病病理方面的准确性与长期使用标准的脑脊液检测相当,准确率达90%以上。该研究采用监管机构预先设定的截断值,并在美国及瑞典的记忆门诊与初级保健队列中完成验证。目前该检测已在欧洲、美国和日本获批,临床主要推荐用于伴认知症状患者的专科评估,初级保健落地工作仍在推进中。

推荐理由

研究在多国临床队列中验证了已获批血液检测与脑脊液及PET的准确性对比,提示该检测方法或可减少阿尔茨海默病患者的有创腰椎穿刺需求。

正文 · 原文
blood test
Credit: Artem Podrez from Pexels

A new study in Nature Aging from Lund University in Sweden shows that improved blood tests for the diagnosis of Alzheimer's disease can now be used with accuracy similar to that of the cerebrospinal fluid tests that have long been the standard in health care. The blood test has been approved for use in Europe, the U.S. and Japan, among other places. The researchers hope that doctors will now gradually be able to use it more widely—and that, in many cases, patients will be able to avoid the more invasive cerebrospinal fluid test.

"These new findings are based on cutoff values that directly reflect clinical practice. The results show that this improved blood test, which has previously received FDA approval and CE marking for clinical use, is just as accurate as the established cerebrospinal fluid test—detecting Alzheimer's disease pathology with at least 90% accuracy.

"It is the first time this has been demonstrated," says Noëlle Warmenhoven, a doctoral student in the Clinical Memory Research Unit at Lund University.

PET imaging was used to verify that the blood tests are indeed accurate. It can be used to confirm the presence of Alzheimer's-related changes. One in five women and one in 10 men develop Alzheimer's disease during their lifetime, but the tools available to the health care system for making a diagnosis have been limited. While specialized memory clinics have access to advanced techniques such as PET scans and cerebrospinal fluid tests, primary care is in great need of simpler and quicker diagnostic methods.

"Previous studies have used cerebrospinal fluid tests as a reference standard. Based on those articles, there are many clinicians that therefore believe the new blood tests are good, but probably not as good as the cerebrospinal fluid tests we already use. However, the findings of this new study contradict this and suggest that a blood test is just as accurate as cerebrospinal fluid testing," says Sebastian Palmqvist, associate professor and senior lecturer in neurology at Lund University and senior consultant at the Memory Clinic, Skåne University Hospital.

A key aspect of the study design is that the researchers have used regulator-approved, predefined cutoff values to determine whether the test result is positive, inconclusive or negative. Previous research has often evaluated the accuracy of blood tests using cutoff values developed specifically for the study in question. The problem is that such cutoff values are not the ones subsequently used in clinical practice.

"For example, you could establish a cutoff that perfectly distinguishes between people with and without Alzheimer's disease in Study A. But, if the same cutoff is then used in Study B, where the proportion of people without Alzheimer's is significantly higher, this could lead to many false-positive results," says Warmenhoven.

Predefined cutoffs, on the other hand, are designed to be broadly applicable in clinical practice, and are the cutoff values that physicians will actually use. The study has shown that the blood tests and cerebrospinal fluid tests perform equally well in an American research cohort, a Swedish memory clinic cohort and a Swedish primary care cohort. However, as Palmqvist points out, at present the blood test is only recommended in memory clinics and other specialist health care units.

"However, work is currently underway to determine what implementation in primary care might look like. Further down the line, it may also become relevant to screen people with no memory problems at all, should drug treatments prove effective at that stage," says Palmqvist.

About the blood test

The blood test shows a positive or negative result for Alzheimer's disease, but may also return an inconclusive result. Further investigation using a PET scanner or a cerebrospinal fluid test may then be required for a more reliable diagnosis. The patient must have cognitive symptoms.

The blood test measures the protein p-tau217, a biomarker specific to Alzheimer's disease. The U.S. blood test, which has also been approved for use, measures p-tau217 in combination with the protein Aβ42 (amyloid-beta 42), a protein that begins to accumulate in the brain and form plaques in people with Alzheimer's disease. However, the Lund researchers have previously shown—and demonstrate once again in the latest study—that this combination does not necessarily perform better than measuring p-tau217 on its own.

On cutoff values and reference standards

Cutoff values are used to determine whether a test result is positive, negative or inconclusive. Previously, blood tests were only available in a research context, which meant that researchers had to calculate their own cutoff values—values that worked best for that particular study group and are not generally used in other studies. This means that test performance may vary between studies, depending on how well the cutoff has been chosen. Now that blood tests have been approved by the regulatory authorities, the manufacturers can provide cutoffs alongside the blood test to determine the test result.

To assess how effective a blood test is at detecting Alzheimer's, it is compared with a reference standard—an established method, such as a PET scan or cerebrospinal fluid testing. These are used as a reference to determine whether the changes associated with the disease are present in the brain. The aim is for the blood test to produce the same result as the reference standard as accurately as possible.

Publication details

Noëlle Warmenhoven et al., Comparing plasma p-tau217 and plasma p-tau217/Aβ42 with CSF biomarkers for assessing Alzheimer's disease pathology, Nature Aging (2026). DOI: 10.1038/s43587-026-01259-z

Journal information: Nature Aging

Who's behind this story?

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Improved blood test offers less invasive way to detect Alzheimer's disease (2026, November 19) retrieved 19 November 2026 from https://medicalxpress.com/news/2026-11-blood-invasive-alzheimer-disease.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com